Scribd Logo
Загрузить

Добро пожаловать в Scribd!

  • ESC EAS Guidelines For The Management of Dyslipidaemias - Slideset

    Загружено:

    jleebm
    16 просмотров40 страниц
    APPROACH GLOBAL RISK LEVELS OF RISK GRADING INTERVENTION LEVELS TARGETS INTERVENTION strategies as a function of total CV risk and LDL-C level

    Исходное описание:

    Оригинальное название

    ESC EAS Guidelines for the Management of Dyslipidaemias -Slideset

    Авторское право

    © Attribution Non-Commercial (BY-NC)

    Доступные форматы

    PDF, TXT или читайте онлайн в Scribd

    Этот документ был вам полезен?

    Это неприемлемый материал?

    Пожаловаться на этот документ
    APPROACH GLOBAL RISK LEVELS OF RISK GRADING INTERVENTION LEVELS TARGETS INTERVENTION strategies as a function of total CV risk and LDL-C level

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    16 просмотров40 страниц

    ESC EAS Guidelines For The Management of Dyslipidaemias - Slideset

    Загружено:

    jleebm
    APPROACH GLOBAL RISK LEVELS OF RISK GRADING INTERVENTION LEVELS TARGETS INTERVENTION strategies as a function of total CV risk and LDL-C level

    Авторское право:

    Attribution Non-Commercial (BY-NC)
    Скачайте в формате PDF, TXT или читайте онлайн в Scribd
    Отметить как неприемлемый контент
    из 40

    www.escardio.

    org

    BACKGROUND

    CLASSES OF RECOMMENDATIONS LEVEL OF EVIDENCE

    www.escardio.org

    Classes of recommendations

    www.escardio.org

    Levels of evidence

    www.escardio.org

    THE APPROACH

    GLOBAL RISK LEVELS OF RISK GRADING INTERVENTION LEVELS TARGETS

    www.escardio.org

    RISK LEVELS

    THE SCORE RISK OF CV MORTALITY OF 5 CORRESPONDS TO 15 IN THE EQUATIONS CONSIDERING MOTALITY AND MORBILITY

    www.escardio.org

    SCORE chart: 10 year risk of fatal cardiovascular disease (CVD) in populations at high CVD risk

    www.escardio.org

    Risk function without high-density lipoprotein-cholesterol (HDL-C) for men in populations at high cardiovascular disease risk

    www.escardio.org

    Relative risk chart

    www.escardio.org

    Risk will also be higher than indicated in the charts in:

    www.escardio.org

    THE APPROACH

    GLOBAL RISK LEVELS OF RISK GRADING INTERVENTION LEVELS TARGETS

    www.escardio.org

    Intervention strategies as a function of total CV risk and LDL-C level

    www.escardio.org

    THE APPROACH

    GLOBAL RISK LEVELS OF RISK GRADING INTERVENTION LEVELS TARGETS

    www.escardio.org

    Recommendations for treatment targets for LDL-C

    www.escardio.org

    THE APPROACH

    LIPID ANALYSES

    www.escardio.org

    Recommendations for lipid analyses as treatment target in the prevention of CVD

    www.escardio.org

    THE APPROACH

    LIFESTYLE CHANGES

    www.escardio.org

    Definition of central obesity

    www.escardio.org

    Dietary recommendations to lower TC and LDL-C

    www.escardio.org

    Summary of lifestyle measures and healthy food choices for managing total cardiovascular risk

    www.escardio.org

    THE APPROACH

    DRUG THERAPY

    www.escardio.org

    Recommendations for the pharmacological treatment of hypercholesterolaemia

    www.escardio.org

    Recommendations for drug treatment of HTG

    www.escardio.org

    Recommendations if drug treatment of low HDL-C is considered

    www.escardio.org

    THE APPROACH

    GENETIC DYSLIPIDAEMIAS

    www.escardio.org

    Genetic disorders of lipoprotein metabolism

    www.escardio.org

    Diagnostic criteria for the clinical diagnosis of HeFH according to MedPed and WHO

    www.escardio.org

    THE APPROACH

    SPECIFIC POPULATIONS

    www.escardio.org

    Management of dyslipidaemia in women

    www.escardio.org

    Recommendations for treatment of dyslipidaemia in the elderly

    www.escardio.org

    Recommendations for treatment of dyslipidaemia in diabetes

    www.escardio.org

    Recommendations for lipid lowering drugs in patients with moderate to severe CKD
    (stages 24, GFR 1589 mL/min/1.73 m2)

    www.escardio.org

    Recommendations for lipid-lowering drugs in patients with PAD

    www.escardio.org

    Recommendations for lipid-lowering drugs for primary and secondary prevention of stroke

    www.escardio.org

    THE APPROACH

    ADHERENCE AND COMPLIANCE

    www.escardio.org

    Hints to help adherence to lifestyle changes

    www.escardio.org

    Tips to help compliance with multiple drug therapies

    www.escardio.org

    Percentage reduction of LDL-C requested to achieve goals as a function of the starting value

    www.escardio.org

    A systematic review and meta-analysis on the therapeutic equivalence of statins

    www.escardio.org

    THE PUBLICATION

    doi:10.1016/j.atherosclerosis.2011.06.028

    www.escardio.org

    Вам также может понравиться